Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?


  • Heng Marie Amélie
  • Padovani Laetitia
  • Dory-Lautrec Philippe
  • Gentet Jean Claude
  • Verschuur Arnaud
  • Pasquier Eddy
  • Figarella-Branger Dominique
  • Scavarda Didier
  • André Nicolas

document type



The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low- grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow- up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression-free survival in children with LGG.

more information